Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MGLL | Q99685 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.35 |
| ▸ | SSTR3 | P32745 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | BCL9 | O00512 | 1/20 | 0.33 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL556964 | 0.88 | KMT2A (0.49) | KMT2AMGLLFAAHTRPV1EPHX2 | |
| SCHEMBL31548905 | 0.85 | KMT2A (0.46) | KMT2AMGLLFAAHTRPV1EPHX2 | |
| SCHEMBL7912741 | 0.83 | KMT2A (0.53) | KMT2AMGLLFAAHTRPV1EPHX2 | |
| SCHEMBL3829326 | 0.82 | MGLL (0.54) | KMT2AMGLLFAAHTRPV1EPHX2 | |
| SCHEMBL26689378 | 0.81 | ALDH1A1 (0.39) | SSTR1SSTR3HTR2AALDH1A1LMNA | |
| SCHEMBL26689244 | 0.80 | MGLL (0.43) | KMT2AMGLLHTR2AALDH1A1LMNA | |
| SCHEMBL26568472 | 0.80 | KMT2A (0.45) | KMT2AMGLLFAAHTRPV1ALDH1A1 | |
| SCHEMBL14966279 | 0.78 | HTR2A (0.44) | KMT2AMGLLEPHX2HTR2AALDH1A1 | |
| SCHEMBL3255050 | 0.77 | KMT2A (0.41) | KMT2AMGLLSSTR1SSTR3EPHX2 | |
| SCHEMBL30678094 | 0.77 | KMT2A (0.59) | KMT2AEPHX2OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260061065-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2026-03-05 | — | — | US | disclosed |
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-12-25 | — | — | US | disclosed |
| WO-2025111450-A1 | ANTI-CD74 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | LES LABORATOIRES SERVIER (FR) | 2025-05-30 | — | — | WO | disclosed |
| WO-2025111431-A1 | ANTI-CD7 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | LES LABORATOIRES SERVIER (FR) | 2025-05-30 | — | — | WO | disclosed |
| EP-4525928-A1 | ANTIBODY DRUG CONJUGATES | Novartis AG (CH) | 2025-03-26 | — | — | EP | disclosed |
| EP-4525927-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | Novartis AG (CH) | 2025-03-26 | — | — | EP | disclosed |
| WO-2023225359-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023223097-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | BID, BCL2, MCL1 | KMT2A 719/4885MGLL 4443/4885FAAH 4029/4885 |
| US-20260061065-A1 | ANTIBODY DRUG CONJUGATES | FCGR2A, FCGR3B, BCL3 | KMT2A 2434/4885MGLL 3708/4885FAAH 1827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.